EEG signatures of cognitive decline after mild SARS-CoV-2 infection: an age-dependent studyResearch Published on 2024-06-202024-09-05 Journal: BMC Medicine [Category] update2024, [키워드] cognitive impact EEG Long COVID mild illness SARS-CoV-2 [DOI] 10.1186/s12916-024-03481-1 PMC 바로가기 [Article Type] Research
Real-World Evidence for COVID-19 Delta Variant’s Effects on the Digestive System and Protection of Inactivated Vaccines from a Medical Center in Yangzhou, China: A Retrospective Observational StudyObservational Study Published on 2022-08-192022-10-04 Journal: International journal of clinical practice [Category] SARS, 바이오마커, 변종, 임상, [키워드] addition Affect alanine aminotransferase ALT analysis of variance ANOVA AST Bilirubin biochemical center changes in Chinese Cohort Coronavirus disease 2019 COVID-19 Critical Critical disease Delta delta variant diagnosed digestive system dysfunction early stage Effect evaluate function Gastrointestinal symptom global public health IL-6 level Inactivated vaccine inactive Infection interleukin 6 (IL-6 investigated lactate dehydrogenase LDH liver dysfunction marker mild illness moderate no significant difference p value Patient prevalent Prevent promoted PROTECT protection public health reported respiratory tract retrospective serum severity Significant significant difference significantly more Sinopharm Sinovac statistically significant Symptom System three group three groups total bilirubin Treatment Vaccine variant was used [DOI] 10.1155/2022/7405448 PMC 바로가기 [Article Type] Observational Study
Advances in the Omicron variant developmentOmicron 변종 개발의 발전Review Published on 2022-07-012022-09-11 Journal: Journal of internal medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition advance Alpha Amino acid amino acids Antiviral antiviral agent Antiviral agents antiviral drugs approved Beta booster dose booster doses Casirivimab circulating coronavirus COVID-19 Delta disease dominant dose drug effective entry of SARS-CoV-2 Epidemiology epitope Epitopes Gamma greater greater transmissibility growth advantage Health Organization humoral Imdevimab Immune escape incidence Infection inhibit Mild mild illness molecular molnupiravir monoclonal monoclonal antibodies monoclonal antibody mutations offer omicron Omicron variant pandemic Paxlovid pharmacological agent pharmacological agents Remdesivir Research respiratory SARS-CoV-2 SARS-CoV-2 virus severe acute respiratory syndrome Coronavirus Spike protein Spread the spike protein therapeutic to define Transmissibility vaccination Vaccine Vaccines variant variants Viral viral replication VoC WHO World Health Organization [DOI] 10.1111/joim.13478 PMC 바로가기 [Article Type] Review
Associations between physical activity prior to infection and COVID-19 disease severity and symptoms: results from the prospective Predi-COVID cohort studyObservational Study Published on 2022-04-292022-10-05 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI age approach Asymptomatic baseline chest pain cohort study collected COVID-19 COVID-19 disease severity COVID-19 infection cross-sectional disease severity dry cough effective Epidemiology fatigue female headache highest Hospitalised patients Illness severity Infection IQR lower risk Luxembourg mild illness moderate Patient physical activity prevalent Primary outcome public health questionnaire reduced risk reverse transcription-PCR SARS-COV-2 infection secondary outcome Self-reported symptoms severity severity of COVID-19 Sports Medicine Symptom Symptoms tested the disease the median Volunteer [DOI] 10.1136/bmjopen-2021-057863 PMC 바로가기 [Article Type] Observational Study
Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel병원 환경에서 코로나바이러스 질병 2019 치료를 위한 Favipiravir 사용Article Published on 2022-03-292022-09-11 Journal: International journal of clinical practice [Category] SARS, 치료제, [키워드] 95% CI 95% confidence interval Admission Adverse drug reaction Adverse drug reactions age Analysis analyzed caution clinical evidence clinical information collected Complete coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids Course COVID-19 COVID-19 patient COVID-19 pneumonia death during admission Dyspnea elderly patients evidence of examined extension Factor Favipiravir healthcare facility higher risk Hospitalization loss of taste management medication medication treatment mild illness Mild-to-moderate Mortality Most patient Most patients Multivariate analysis occurred Odds ratio outcome Patient patients Pneumonia receiving required Risk factors setting Taste transfer treat treated treating COVID-19 Treatment Treatment outcome [DOI] 10.1155/2022/3098527 PMC 바로가기 [Article Type] Article
Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of PakistanResearch article Published on 2022-03-012022-10-05 Journal: Exploratory Research in Clinical and Social Pharmacy [Category] 신약개발, 치료제, [키워드] addition Administered Antibiotics Anticoagulant antithrombotic therapy Clinical characteristics Clinical severity Cohort concerning conducted Corticosteroid Corticosteroids COVID-19 COVID-19 severity described Dexamethasone died discharged District enrolled evaluate finding heparin hospitalized patient medication medications Mild mild illness moderate multicenter Pakistan Patient patients patients hospitalized pattern Prevalence provided Repurposed drug retrospective SARS-CoV-2 steroid stratified systemic corticosteroid therapeutic option Treatment with COVID-19 [DOI] 10.1016/j.rcsop.2021.100101 [Article Type] Research article
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19Articles Published on 2022-02-282022-10-04 Journal: EClinicalMedicine [Category] 임상, 치료법, [키워드] Analysis analyzed baseline clinical recovery double-blind Effectiveness Efficacy Endpoint enrolled evaluate finding FIVE groups Health high risk investigated IQR laboratory-confirmed SARS-CoV-2 infection median Mild mild illness Moderate COVID-19 nitazoxanide Odds ratio Outpatient participant Patient Placebo placebo-controlled clinical trial primary analysis primary endpoint progressed progression proportion Randomized reducing reductions in risk reduction Safe sustained Symptom symptom onset therapy treated Treatment Trial [DOI] 10.1016/j.eclinm.2022.101310 PMC 바로가기 [Article Type] Articles
The presentation, course and outcome of COVID-19 infection in people with Prader-Willi syndrome: unexpected findings from an international surveyResearch Published on 2022-02-212022-10-29 Journal: Orphanet Journal of Rare Diseases [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] Adults Affect age asked asymptomatic infection BMI children Cohort Complete conditions Course COVID-19 COVID-19 infection Diabetes Mellitus died disorder dry cough Effect Evidence family FIVE Genetic hospital Hypothesis hypothesised illness incidence Innate immunity intensive care International Length less mild illness obese obesity organization outcome outcomes over oxygen pandemic parent Prader-Willi syndrome presenting symptom professional promoted questionnaire raised respiratory disorders response Result Sex significantly supplementary material supported Symptoms temperature underlying condition Ventilated viral infection viral infections [DOI] 10.1186/s13023-022-02228-6 PMC 바로가기 [Article Type] Research
Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019Article Published on 2022-02-142022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Coagulopathy coronavirus disease COVID-19 COVID-19 infection COVID-19 patient Critical facilitated Infection infections mechanism Mild mild illness moderate Patient patients with COVID-19 plasma Platelet platelet activation Pneumonia receptor sCLEC-2 severity of COVID-19 significantly higher thrombosis triggered were measured [DOI] 10.3390/jcm11040985 PMC 바로가기 [Article Type] Article
Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222감염 정도가 다양하고 AZD1222의 단일 투여 후 개인에서 SARS-CoV-2 단백질에 대한 면역 반응의 동역학Research Article Published on 2022-01-272022-09-12 Journal: Clinical and experimental immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] ACE2 Alpha angiotensin antibody AZD1222 cohorts comparable country declined doses highest IgA IgA antibody IgA response IgG IgG antibody IgG response immune response immune responses individual individuals investigated Kinetics less mild illness N protein natural infection outbreak Patient Protein RBD receptor Receptor binding domain reduce reduced remained S2 subunit SARS-CoV-2 SARS-CoV-2 protein SARS-CoV-2 proteins Severity of infection significantly significantly lower single dose tested the antibody response the SARS-CoV-2 titre vaccination vaccinee vaccinees VOCs were assessed wild type [DOI] 10.1093/cei/uxac009 PMC 바로가기 [Article Type] Research Article